Medicine and Dentistry
Metastatic Colorectal Cancer
100%
Colorectal Carcinoma
65%
Overall Survival
58%
Neoplasm
41%
Malignant Neoplasm
39%
Metastatic Carcinoma
36%
Progression Free Survival
27%
Diseases
25%
Radiation Therapy
24%
Surgery
22%
Biological Marker
20%
Hazard Ratio
20%
Clinical Trial
20%
Breast Cancer
20%
Non Small Cell Lung Cancer
20%
Epidermal Growth Factor Receptor
19%
Chemoradiotherapy
19%
Cancer Registry
17%
Cancer Therapy
17%
Cancer
16%
Medical Oncology
15%
Fluorouracil
14%
Meta-Analysis
14%
Systemic Therapy
13%
Cetuximab
13%
Primary Tumor
13%
Fluoropyrimidine
13%
Cancer Survival
13%
Arm
13%
Recurrent Disease
12%
Esophageal Adenocarcinoma
12%
Immunotherapy
12%
Rectum Cancer
12%
Randomized Controlled Trial
12%
Pooled Analysis
11%
Oncologist
11%
Cisplatin
11%
Circulating Tumor DNA
11%
Panitumumab
11%
Immune Checkpoint Inhibitor
11%
Diagnosis
10%
Clinician
10%
Cancer Mortality
10%
Abdominal Cancer
10%
Adjuvant Therapy
10%
Hepatectomy
10%
Adverse Event
10%
Oncology
9%
Proportional Hazards Model
9%
Lung
9%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colorectal Cancer
82%
Chemotherapy
62%
Colorectal Carcinoma
54%
Overall Survival
46%
Neoplasm
39%
Cetuximab
37%
Progression Free Survival
30%
Biological Marker
28%
Malignant Neoplasm
28%
Epidermal Growth Factor Receptor
28%
Clinical Trial
24%
Irinotecan
19%
Diseases
19%
Non Small Cell Lung Cancer
16%
Fluorouracil
16%
Chemoradiation Therapy
16%
Immune Checkpoint Inhibitor
14%
Circulating Tumor DNA
13%
Monoclonal Antibody
12%
Randomized Controlled Trial
11%
Atezolizumab
11%
Adverse Event
11%
Cancer Registry
10%
Oxaliplatin
10%
Fluoropyrimidine
10%
Cisplatin
9%
Recurrent Disease
9%
Esophageal Adenocarcinoma
9%
Panitumumab
9%
Proton Pump Inhibitor
9%
Rectum Cancer
9%
Metastasis
8%
Biological Product
8%
Group Trial
7%
Cohort Study
7%
Cancer of Unknown Primary Site
6%
Durvalumab
6%
Immunotherapy
6%
Bevacizumab
6%
Pancreas Cancer
6%
Combination Therapy
5%
Docetaxel
5%
Obesity
5%
Cancer Mortality
5%
Placebo
5%
Pharmacokinetic
5%
Abdominal Cancer
5%